PATENT CLAIM ANALYSIS

Application Number: 16148265
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "063000"]

Abstract:
The present disclosure provides a compound of general Formula (I) having c-abl kinase inhibitory activity or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method useful to treat or prevent neurodegenerative diseases using the compound.

Claim (Index 19):
The compound of  claim 18 , wherein the compound is selected from the group consisting of:\n N-(6-(2-fluoro-6-methylphenyl)benzo[d]thiazol-2-yl)cyclobutanecarboxamide; N-(6-(4-methylpyridin-3-yl)benzo[d]thiazol-2-yl)cyclobutanecarboxamide; and N-(6-(5-fluoro-4-methylpyridin-3-yl)benzo[d]thiazol-2-yl)cyclobutanecarboxamide.

Metadata:
- Claim Count in Document: 19.0
- Percentile: 97.0
- Lexical Diversity: 1.18919
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14776280', '15335279', '15851434', '15025996', '13780557']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8383414473237615
- 35 USC 102 Novelty (BERT): 0.5367063643754841
- Combined Prediction Score: 0.8081779390289338
- Mean Citation Score: 362.723298
- Max Citation Score: 383.57654
- Similarity Product: 310.2775318917585

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test